TREM2 and early-onset autosomal dominant Alzheimer disease: The soluble variant of TREM2 (sTREM2) has emerged as a valuable biomarker for AD pathology and cognitive degeneration, as sTREM2 levels in cerebrospinal fluid (CSF) increase during the early symptomatic phase of Alzheimer’s disease [78,84].